Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms

Kelly L. Warfield, Katie A. Howell, Hong Vu, Joan Geisbert, Gary Wong, Sergey Shulenin, Stephanie Sproule, Frederick W. Holtsberg, Daisy W. Leung, Gaya K. Amarasinghe, Dana L. Swenson, Sina Bavari, Gary P. Kobinger, Thomas Geisbert, M. Javad Aman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood. Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods. Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.

Original languageEnglish (US)
Pages (from-to)S553-S564
JournalThe Journal of infectious diseases
Volume218
Issue number5
DOIs
StatePublished - Nov 22 2018

Fingerprint

Ebolavirus
Primates
Glycoproteins
Vaccines
Antibodies
Nucleoproteins
Virion
Ebola Vaccines
Antibody Formation
Ebola Hemorrhagic Fever
Viral Load
Adenoviridae
Anti-Idiotypic Antibodies
Immunoglobulin G
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Warfield, K. L., Howell, K. A., Vu, H., Geisbert, J., Wong, G., Shulenin, S., ... Aman, M. J. (2018). Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. The Journal of infectious diseases, 218(5), S553-S564. https://doi.org/10.1093/infdis/jiy316

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. / Warfield, Kelly L.; Howell, Katie A.; Vu, Hong; Geisbert, Joan; Wong, Gary; Shulenin, Sergey; Sproule, Stephanie; Holtsberg, Frederick W.; Leung, Daisy W.; Amarasinghe, Gaya K.; Swenson, Dana L.; Bavari, Sina; Kobinger, Gary P.; Geisbert, Thomas; Aman, M. Javad.

In: The Journal of infectious diseases, Vol. 218, No. 5, 22.11.2018, p. S553-S564.

Research output: Contribution to journalArticle

Warfield, KL, Howell, KA, Vu, H, Geisbert, J, Wong, G, Shulenin, S, Sproule, S, Holtsberg, FW, Leung, DW, Amarasinghe, GK, Swenson, DL, Bavari, S, Kobinger, GP, Geisbert, T & Aman, MJ 2018, 'Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms', The Journal of infectious diseases, vol. 218, no. 5, pp. S553-S564. https://doi.org/10.1093/infdis/jiy316
Warfield, Kelly L. ; Howell, Katie A. ; Vu, Hong ; Geisbert, Joan ; Wong, Gary ; Shulenin, Sergey ; Sproule, Stephanie ; Holtsberg, Frederick W. ; Leung, Daisy W. ; Amarasinghe, Gaya K. ; Swenson, Dana L. ; Bavari, Sina ; Kobinger, Gary P. ; Geisbert, Thomas ; Aman, M. Javad. / Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. In: The Journal of infectious diseases. 2018 ; Vol. 218, No. 5. pp. S553-S564.
@article{0b3948ecc3d94a4d90001e46534e127f,
title = "Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms",
abstract = "Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood. Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods. Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.",
author = "Warfield, {Kelly L.} and Howell, {Katie A.} and Hong Vu and Joan Geisbert and Gary Wong and Sergey Shulenin and Stephanie Sproule and Holtsberg, {Frederick W.} and Leung, {Daisy W.} and Amarasinghe, {Gaya K.} and Swenson, {Dana L.} and Sina Bavari and Kobinger, {Gary P.} and Thomas Geisbert and Aman, {M. Javad}",
year = "2018",
month = "11",
day = "22",
doi = "10.1093/infdis/jiy316",
language = "English (US)",
volume = "218",
pages = "S553--S564",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms

AU - Warfield, Kelly L.

AU - Howell, Katie A.

AU - Vu, Hong

AU - Geisbert, Joan

AU - Wong, Gary

AU - Shulenin, Sergey

AU - Sproule, Stephanie

AU - Holtsberg, Frederick W.

AU - Leung, Daisy W.

AU - Amarasinghe, Gaya K.

AU - Swenson, Dana L.

AU - Bavari, Sina

AU - Kobinger, Gary P.

AU - Geisbert, Thomas

AU - Aman, M. Javad

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood. Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods. Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.

AB - Background: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood. Methods: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods. Results: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. Conclusions: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.

UR - http://www.scopus.com/inward/record.url?scp=85057186898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057186898&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy316

DO - 10.1093/infdis/jiy316

M3 - Article

C2 - 29939318

AN - SCOPUS:85057186898

VL - 218

SP - S553-S564

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -